Phase I Clinical Trial of GEN2-Recombinant COVID-19 Vaccine (CHO Cells) in Healthy People Aged 18 and Above

Clinical trial NCT05408312 · COMPLETED

Trial details

NCT number: NCT05408312
Sponsor: National Vaccine and Serum Institute, China
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

COVID-19 Pneumonia

Start date: 2022-06-18
Primary completion: 2024-02-28
Enrollment: 234

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.